Login to Your Account

First New Oral Antibiotic for C. difficile in 25 Years

Optimer Pharmaceuticals Buoyed by Unanimous Vote

By Mari Serebrov

Wednesday, April 6, 2011
WASHINGTON – Optimism, and eight years of hard work, paid off for Optimer Pharmaceuticals Inc. Tuesday when an FDA advisory committee unanimously recommended approval of Dificid (fidaxomicin) as a treatment for Clostridium difficile infection (CDI).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription